Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

doi:10.1158/1078-0432.CCR-25-4382

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Mar 2026

Waliany Sarah, Cooper Alissa J, Liu Stephen V, Gautschi Oliver, Rotow Julia K, Smith Katherine Emilie Rhoades, Weber Urs M, Lee Dae Ho, Loong Herbert H F, Patel Jyoti D, Pennell Nathan A, Nagasaka Misako, Patel Shetal A, Tan Daniel S W, Solomon Benjamin J, Kim Tae Min, Pall Georg, Riess Jonathan W, Sun Lova, Früh Martin, Uy Natalie F, Gadgeel Shirish, Feng Jamie, Do Andrew, Falcon Christina, Leighl Natasha B, Baik Christina S, Lai Gillianne G Y, Ou S Ignatius, Cheung Kingsley S Y, Patil Tejas, Mansfield Aaron S, Weiler Daniela, Yeap Beow Y, Wirth Lori J, Gainor Justin F, Drilon Alexander, Lin Jessica J

Abstract excerpt

PURPOSE: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. EXPERIMENTAL DESIGN: We established "RETgistry," a global consortium of patients with advanced RET-altered solid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Pyrimidines

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41537704
DOI: 10.1158/1078-0432.CCR-25-4382
PMCID: PMC12912800

Genes

RET
SRI
MET
APC
CDKN2A
KEAP1
KRAS
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.PMID 41537704Read ↗

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.Semantic proximity Read ↗

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

Precision oncology for RET-related tumorsSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.